Kamdar M, Solomon SR, Arnason J, Johnston PB, et al. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. J Clin Oncol 2025 Jul 7:JCO2500399. doi: 10.1200/JCO-25-00399.
PMID: 40623279